Federal grants to Leukogene Therapeutics Inc
Leukogene Therapeutics Inc in Mount Pleasant, South Carolina received $3.2 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Cancer Treatment Research, with $2.8 million. In fiscal 2025 it was awarded $742,887.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$3.2 million
- Awards5
- Awarded in FY 2025$742,887
- Largest award$2.3 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $362,118 |
| FY 2022 | 2 | $671,746 |
| FY 2023 | 1 | $708,144 |
| FY 2024 | 2 | $742,426 |
| FY 2025 | 1 | $742,887 |
Programs that fund Leukogene Therapeutics Inc
| Program | Awards | Amount |
|---|---|---|
| Cancer Treatment Research | 3 | $2.8 million |
| Cancer Cause and Prevention Research | 2 | $400,000 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $3.2 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| AGR2-SUPERANTIGEN vaccine conjugate for the treatment of pancreaticductal adenocarcinoma - project summary/abstract pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Poor survival rates are largely due to the late stage at which pdac is diagnosed and a lack of effectiv | Cancer Treatment Research | July 31, 2023 | $2.3 million |
| Bispecific t cell engagers for the treatment of pancreatic ductal adenocarcinoma - ---project summary/abstract ---- pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Poor survival rates are largely due to the late stage at which pdac is diagnosed and a lack of effectiv | Cancer Treatment Research | September 24, 2021 | $361,657 |
| AGR2-SUPERANTIGEN vaccine conjugate for the treatment of pancreaticductal adenocarcinoma - project summary/abstract pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Poor survival rates are largely due to the late stage at which pdac is diagnosed and a lack of effectiv | Cancer Cause and Prevention Research | May 13, 2022 | $351,275 |
| AGR2-SUPERANTIGEN vaccine conjugate for the treatment of pancreaticductal adenocarcinoma - project summary/abstract pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Poor survival rates are largely due to the late stage at which pdac is diagnosed and a lack of effectiv | Cancer Treatment Research | August 29, 2022 | $238,644 |
| AGR2-SUPERANTIGEN vaccine conjugate for the treatment of pancreaticductal adenocarcinoma - project summary/abstract pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Poor survival rates are largely due to the late stage at which pdac is diagnosed and a lack of effectiv | Cancer Cause and Prevention Research | January 17, 2024 | $48,725 |
Questions people ask
How much federal grant money does Leukogene Therapeutics Inc get?
$3.2 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Leukogene Therapeutics Inc the most?
The Department of Health and Human Services, with $3.2 million in 5 awards.
What is Leukogene Therapeutics Inc's largest federal grant?
$2.3 million under Cancer Treatment Research, with its first action in the period on July 31, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Leukogene Therapeutics Inc?
Its largest are Cancer Treatment Research and Cancer Cause and Prevention Research.
Other grant recipients in Mount Pleasant
- Southeast Coastal Ocean Observing Regional Association
- SC State Ports Authority
- Town of Mount Pleasant Town Hall
- Lipo-Immuno Tech LLC
- Dee Norton Lowcountry Childrens Center Inc
- Apex Orthopaedic Technologies LLC
- Gulf and Caribbean Fisheries Institute
Largest federal grant recipients in South Carolina · Federal grants in South Carolina